Myriad Genetics Inc (MYGN) Stock AnalysisMYGNStock AnalysisMyriad Genetics Inc

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Myriad Genetics Inc is not a good buy right now due to its recent poor performance and negative outlook. The current price is $3.16, which is close to the lowered analyst targets of $3.20 and $3.00. The company reported a significant year-over-year revenue decline of 11% in Q2 2026, and its forward P/E ratio is extremely high at 54.05, indicating that the stock is overvalued given its current financial struggles.

14 analysts cover MYGN: 2 rate it Buy, 9 Hold and 3 Sell. The average price target is 7.38.